Keros Therapeutics, Inc. $KROS is ADAR1 Capital Management LLC's 8th Largest Position

Key Points

• ADAR1 Capital Management LLC significantly increased its stake in Keros Therapeutics by 6,294.5% in Q1, now holding approximately $15.15 million worth of shares.
• Keros Therapeutics recently reported an EPS of (0.76), exceeding consensus estimates, though its revenue of $0.02 million fell short of the expected $3.83 million.
• The stock has received mixed ratings from analysts, with a consensus rating of "Moderate Buy" and a target price of $30.00.

ADAR1 Capital Management LLC grew its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 6,294.5% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,486,461 shares of the company's stock after acquiring an additional 1,463,215 shares during the quarter. Keros Therapeutics accounts for approximately 2.8% of ADAR1 Capital Management LLC's investment portfolio, making the stock its 8th biggest position. ADAR1 Capital Management LLC owned about 3.66% of Keros Therapeutics worth $15,147,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Wells Fargo & Company MN increased its holdings in Keros Therapeutics by 37.6% in the 4th quarter. Wells Fargo & Company MN now owns 15,208 shares of the company's stock valued at $241,000 after buying an additional 4,153 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Keros Therapeutics by 1.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 155,163 shares of the company's stock worth $2,456,000 after acquiring an additional 2,727 shares in the last quarter. MetLife Investment Management LLC increased its stake in Keros Therapeutics by 6.0% in the fourth quarter. MetLife Investment Management LLC now owns 18,098 shares of the company's stock valued at $286,000 after acquiring an additional 1,027 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in Keros Therapeutics by 140.1% in the fourth quarter. The Manufacturers Life Insurance Company now owns 40,356 shares of the company's stock valued at $639,000 after acquiring an additional 23,550 shares during the last quarter. Finally, Northern Trust Corp raised its position in Keros Therapeutics by 11.3% during the fourth quarter. Northern Trust Corp now owns 296,467 shares of the company's stock valued at $4,693,000 after purchasing an additional 30,111 shares in the last quarter. Institutional investors and hedge funds own 71.56% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on KROS shares. HC Wainwright lowered their price target on Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating for the company in a report on Friday, August 8th. Scotiabank decreased their target price on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a research report on Monday, May 12th. Wedbush reissued a "neutral" rating and issued a $15.00 target price on shares of Keros Therapeutics in a report on Friday, May 30th. Finally, Bank of America downgraded shares of Keros Therapeutics from a "buy" rating to a "neutral" rating and reduced their price target for the company from $32.00 to $18.00 in a research note on Tuesday, June 10th. Seven investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, Keros Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $30.00.

Keros Therapeutics Stock Performance

Shares of NASDAQ:KROS traded up $0.04 during midday trading on Friday, reaching $15.59. The company's stock had a trading volume of 537,578 shares, compared to its average volume of 472,423. Keros Therapeutics, Inc. has a fifty-two week low of $9.12 and a fifty-two week high of $72.37. The firm has a 50 day moving average price of $14.39 and a two-hundred day moving average price of $13.33. The firm has a market capitalization of $633.19 million, a price-to-earnings ratio of 50.29, a PEG ratio of 2.01 and a beta of 1.06.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.76) earnings per share for the quarter, topping analysts' consensus estimates of ($1.14) by $0.38. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $3.83 million. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.The firm's revenue for the quarter was up 49002.7% on a year-over-year basis. During the same period in the prior year, the business earned ($1.25) EPS. As a group, research analysts anticipate that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.